Jubilant Life Sciences has said that its net profit has risen to Rs 26.69 crore during the third quarter of the financial year mainly due to strong sales even as the company faced a foreign exchange loss of Rs 71 crore.

The company had recorded a net loss Rs 78.39 crore during the same period of the previous year. The company's income from operations increased about 19 per cent to Rs. 1,306 crore during the third quarter from October to December compared to the same period of the previous year, Jubilant Life Sciences said in a statement.

During the first nine months of the year, the company's revenue grew 22 per cent and its EBITDA (earnings before interest, taxes, depreciation and amortisation) recorded a growth of 26 per cent mainly due to strong growth in the pharma segment.

Shyam S Bhartia, CMD, and Hari S Bhartia, co-chairman and MD, Jubilant Life Sciences said, "Our strategy of enhancing presence in identified international markets is delivering results with 28% growth and high 73% contribution to revenue mix."

He also said that the company can maintain its momentum due to strong product pipeline and order book position. The company is also expecting to benefit from vertical integration initiatives.